DB16442InvestigationalVaccines
The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to BNT162b2, BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. Pfizer and BioNTech deemed... Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it.
- Code names
- BNT162b3
Resolves to
Compound
What you can answer from here — as of October 27, 2025
Which companies are running trials of Ganulameran, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account